

Abstract

Introduction: Neuraminidase inhibitors mainly oseltamivir and zanamivir function both as prophylactic and treatment agents for influenza infections. We characterized the antiviral susceptibility of the 2008-2011 influenza A viruses circulating in Kenya by combining both the genotypic data involving known molecular markers in neuraminidase (NA) protein responsible for drug resistance and IC₅₀ data generated from NA inhibition assays.

Materials and Methods: Nasopharyngeal swab specimen from consenting outpatients of age ≥ 2 months were obtained and transported to the National Influenza Center. RT-PCR amplification of NA gene segments was performed on the virus isolates prior to nucleotide sequencing using the BigDye chemistry. Sequences were analyzed using a suite of bioinformatics tools. Drug susceptibility was determined by fluorescent enzyme inhibition assay with known NA inhibitor-resistant and inhibitor-sensitive viruses. IC₅₀ values were determined using curve fitting software, Grafit 7.0.

Results and Discussion: Out of 836 influenza A virus isolates obtained (2008-2011), 108 (13%) were analyzed for markers of resistance to NA inhibitors. 64% (7/11) of the 2008 seasonal influenza A/H1N1 isolates depicted oseltamivir resistant marker H275Y. Influenza A/H3N2 and A/ (H1N1) pdm09 isolates lacked the H275Y mutation. A total of 28 isolates were further subjected to phenotypic susceptibility assay. The mean zanamivir IC₅₀s were 1.75nM, 2.53nM and 1.84nM for the subtypes sH1N1, pH1N1 and H3N2 respectively. Eight of the 2008-2009 sH1N1 isolates analyzed showed highly reduced sensitivity to oseltamivir with IC₅₀s ranges from 73nM-984nM. Pandemic A/H1N1 and A/H3N2 strains obtained between 2009-2011 and 2008-2011 respectively depicted normal sensitivity. The 2011, WHO range and median IC₅₀ values for oseltamivir carboxylate were 257nM-3455nM and 458.2nM; 132nm-2179nM and 191.3nM; 23-378 and 42.3nM for the mutant subtypes sH1N1, pH1N1 and sH3N2 respectively.

Conclusion: Overall genotypic and phenotypic data demonstrate oseltamivir resistance in the 2008-2009, sH1N1 viruses. The H275Y mutation increased the IC₅₀ by 50-100 fold.